Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 20 Oct 2021
FDA expands approval of Dupixent (dupilumab) to include children aged 6 to 11 years with moderate to severe asthma
20 October 2021 - Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years ...
Posted by Michael Wonder on 20 Oct 2021
Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges
20 October 2021 - Medical devices are potentially good candidates for coverage with evidence development schemes, as clinical data at market ...
Posted by Michael Wonder on 20 Oct 2021
ICER publishes final evidence report and policy recommendations on therapies for myasthenia gravis
20 October 2021 - Independent appraisal committee found the evidence is adequate to demonstrate that eculizumab and efgartigimod both provide a ...
Posted by Michael Wonder on 20 Oct 2021
Sales of Biogen’s costly new Alzheimer’s drug fall far short of expectations
20 October 2021 - The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 ...
Posted by Michael Wonder on 20 Oct 2021
Luminopia announces FDA approval of digital therapeutic that uses TV shows to improve vision in children with lazy eye
20 October 2021 - Luminopia One improves vision in children with amblyopia, the leading cause of vision loss in children, and ...
Posted by Michael Wonder on 20 Oct 2021
PHARMAC says all patients who meet criteria will get next generation diabetes drugs, despite concerns
20 October 2021 - PHARMAC says it will fund next generation diabetes drugs for all people with the condition who ...
Posted by Michael Wonder on 20 Oct 2021
TGA approves Brukinsa for another use
20 October 2021 - The second approval for zanubrutinib this month. ...
Posted by Michael Wonder on 20 Oct 2021
Pear Therapeutics launches Pear Prescription Digital Therapeutics Digest, provides roadmap for payer coverage considerations
19 October 2021 - Pear Therapeutics, in collaboration with Avalere Health, today launched the Pear Prescription Digital Therapeutics Digest at ...
Posted by Michael Wonder on 20 Oct 2021
Chiesi Global Rare Diseases announces approval of Ferriprox (deferiprone) in Canada for the treatment of iron overload in sickle cell disease
15 October 2021 - Chiesi Global Rare Diseases announced today that Health Canada has approved Ferriprox (deferiprone) for the treatment of ...
Posted by Michael Wonder on 20 Oct 2021
FDA pre-submission for saliva based glucose test to replace invasive finger prick
19 October 2021 - The iQ Group Global, on behalf of its subsidiary, Life Science Biosensor Diagnostics, is pleased to announce ...
Posted by Michael Wonder on 20 Oct 2021
Bringing a consumer perspective to clinical advice
19 October 2021 - PHARMAC is making changes to the way its advisory committees work to strengthen the input of ...
Posted by Michael Wonder on 20 Oct 2021
CMS grants transitional pass through payment for Carlsmed's aprevo personalized interbody device
19 October 2021 - -Carlsmed announced today that CMS has granted aprevo a transitional pass through payment as part of the ...
Posted by Michael Wonder on 19 Oct 2021
Akero Therapeutics receives FDA fast track designation for efruxifermin for the treatment of NASH
19 October 2021 - Akero Therapeutics today announced that the U.S. FDA has granted fast track designation to its lead program ...
Posted by Michael Wonder on 19 Oct 2021
WHO led programme aims to buy antiviral COVID-19 pills for $10
19 October 2021 - A World Health Organization led programme to ensure poorer countries get fair access to COVID-19 vaccines, tests ...
Posted by Michael Wonder on 19 Oct 2021
Strategies for generic/biosimilar market entry in Australia
19 October 2021 - After surviving the Great Patent Cliff of 2011–2016, the pharma/biopharma industry finds itself in the Second Great ...